Clinical Trial Update: Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating autologous and donor-derived CD7 CAR-T cell therapy for refractory or relapsed T-cell malignancies, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Malignancies

Drugs mentioned

• Autologous CD7 CAR-T therapy (CD7 CAR-T cell therapy)
• Donor-derived CD7 CAR-T therapy (CD7 CAR-T cell therapy)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1, Phase 2 | Status: RECRUITING